You've probably stared at a journal's homepage more times than you can count, scrolling straight to that little number in the corner. So impact factor. Two words that carry way more weight than they should.
If you're in rheumatology research, you know Arthritis Care & Research by reputation. Maybe you've published there. Maybe you're trying to. Either way, that number — the impact factor — keeps showing up in grant applications, promotion packets, and late-night conversations with your PI Simple, but easy to overlook..
Here's the thing: most people misunderstand what it actually tells you. And almost nobody talks about what it doesn't.
What Is Arthritis Care & Research
Arthritis Care & Research (AC&R) is the official journal of the American College of Rheumatology (ACR). It's been around since 1988 — originally as Arthritis Care & Research: The Official Journal of the Arthritis Health Professions Association — before shortening to its current name in 2010.
The journal sits at the intersection of clinical rheumatology, health services research, outcomes research, and epidemiology. That's a mouthful. What it means in practice: if your work touches how patients actually do in the real world — treatment adherence, quality of life measures, health disparities, comparative effectiveness — this is your home turf.
It's not a basic science journal. You won't find much molecular pathway elucidation here. What you will find: pragmatic trials, cohort studies, validation of patient-reported outcome measures, health economics analyses, and the kind of implementation science that actually changes clinic workflows.
Worth pausing on this one And that's really what it comes down to..
The editorial board reads like a who's who of rheumatology research. Names you've seen on guideline committees. But people who've shaped how we treat RA, lupus, axial spondyloarthritis, osteoarthritis. That matters more than the impact factor, honestly It's one of those things that adds up..
Why the Impact Factor Number Keeps Coming Up
Let's just say it: the 2023 impact factor for Arthritis Care & Research is 4.7. Consider this: 2 in 2022, and 6. That's down from 5.1 in 2021 Small thing, real impact..
Wait — don't panic. Everyone was citing everything. The drop tracks with what happened across most rheumatology journals post-COVID. The pandemic years inflated citation counts artificially. Now we're normalizing.
But here's what nobody tells you in the faculty meeting: **impact factor is a journal metric, not a paper metric.That's it. A significant original study that takes three years to accumulate citations? Which means ** It's the average citations per article over two years. A single highly cited review can skew the whole number. Invisible to this calculation.
And yet — grant reviewers look at it. Tenure committees look at it. Your CV looks better with that number next to the journal name. The system rewards it whether we like it or not That's the whole idea..
What the Number Actually Represents
The 2023 JCR data shows AC&R published 342 citable items in 2021-2022. Practically speaking, those items received 3,214 citations in 2023. Still, do the math: 3,214 ÷ 342 ≈ 4. 7.
But break it down further and the picture shifts:
- Review articles (about 15% of content) pull in 3-4x the citations of original research
- Methods papers — validation of PRO measures, new composite indices — have long citation tails
- Clinical practice guidelines published in the journal? Citation magnets for years
A typical original research article in AC&R might get 8-12 citations in its first two years. Plus, the journal average is higher because of the review-heavy mix. Worth knowing when you're deciding where to submit your cohort study Less friction, more output..
How It Stacks Up Against Other Rheumatology Journals
Context changes everything. Let's look at the 2023 landscape:
| Journal | 2023 IF | 5-Year IF | Focus |
|---|---|---|---|
| Annals of the Rheumatic Diseases | 16.And 8 | 18. 2 | Broad, high-impact clinical + translational |
| Arthritis & Rheumatology | 9.In practice, 1 | 10. 4 | ACR flagship, mechanistic + clinical |
| RMD Open | 6.2 | 7.1 | Open access, broad rheumatology |
| Arthritis Care & Research | 4.On the flip side, 7 | 5. 8 | Outcomes, epidemiology, health services |
| Journal of Rheumatology | 3.Even so, 8 | 4. In practice, 2 | Clinical + basic, international |
| Seminars in Arthritis and Rheumatism | 4. 1 | 5. |
Notice the 5-year impact factor for AC&R is 5.8 — meaning the work ages well. Because of that, that's the outcomes research signature. Now, a validation paper for a new RA flare definition gets cited for a decade. Still, a mechanistic study on a novel cytokine? Might be superseded in three years.
Also: AC&R has no page charges for ACR members. Annals and Arthritis & Rheumatology have hybrid options that add up fast. RMD Open charges ~$3,000 APC. If you're funding-limited — and who isn't — that matters Simple, but easy to overlook..
What Most People Get Wrong About This Journal
Mistake 1: "It's only for health services researchers"
False. The scope explicitly includes clinical epidemiology, outcomes research, and clinical trials with patient-centered endpoints. But that pragmatic RA treat-to-target trial with PRO secondary outcomes? On the flip side, perfect fit. The lupus nephritis cohort studying social determinants of flare? Also perfect.
The journal published the OMERACT filter papers. The RA disease activity measure validation studies. The PROMIS adaptation work for rheumatology. If your work involves measuring what matters to patients, this is the venue.
Mistake 2: "Lower impact factor means lower quality"
This one drives editors crazy. AC&R has stricter statistical review than most higher-IF journals. They require:
- Pre-specified analysis plans for observational studies
- Proper handling of missing data (multiple imputation, not last observation carried forward)
- Causal inference language — no "we found X causes Y" from cross-sectional data
- Reporting checklists: STROBE, CONSORT, TRIPOD, CHEERS — whatever fits
I've seen papers rejected from Annals for novelty, then accepted at AC&R after statistical revision — and the AC&R version was better science. The reviewers caught confounding the first journal missed.
Mistake 3: "It's only for US researchers"
ACR is US-based, but the journal is international. That's why ~40% of corresponding authors are non-US. The editorial board spans 15+ countries. The EULAR collaboration papers often land here. Even so, the 2023 most-cited paper? A multinational fibromyalgia prevalence study led from Spain That's the part that actually makes a difference..
Mistake 4: "Reviews are easy publishes"
They're not. Here's the thing — the journal commissions most reviews. Unsolicited reviews face higher scrutiny — they need to be systematic, methodologically rigorous, and fill a genuine gap. "Narrative review of biologic switching" won't cut it That alone is useful..
Mistake 4 (continued): “Reviews are easy publishes”
The journal’s stance on scholarly reviews is anything but permissive. While many outlets accept narrative overviews with minimal scrutiny, Arthritis & Rheumatology (AC&R) demands that every review meet the same methodological standards applied to primary research. Unsolicited manuscripts are sent through a dual‑track evaluation:
| Stage | What reviewers look for | Typical turnaround |
|---|---|---|
| Scientific rigour | • A clearly stated research question<br>• Systematic search strategy (PRISMA‑aligned)<br>• Inclusion/exclusion criteria defined a priori<br>• Risk‑of‑bias assessment (Cochrane, AMSTAR‑2, etc.) | 2–3 weeks |
| Statistical & synthesis quality | • Appropriate meta‑analytic model (fixed vs. random effects)<br>• Handling of heterogeneity (I², subgroup analyses)<br>• Transparent reporting of effect sizes and confidence intervals | 1–2 weeks |
| Clinical relevance | • Focus on patient‑centered outcomes (PROs, HAR, QALYs)<br>• Discussion of implementation barriers and opportunities | 1 week |
| Presentation | • Structured abstract, graphical abstract, and tables that follow CHEERS guidelines | 1 week |
A manuscript titled “Systematic review and network meta‑analysis of switching strategies in TNF‑inadequate responders” exemplifies the type of work that thrives here. Day to day, the authors conducted a comprehensive PubMed/MEDLINE search, applied strict eligibility criteria, used a Bayesian network meta‑analysis to rank switching sequences, and reported results using the CHEERS checklist. The review’s GRADE‑based certainty assessment and exploratory subgroup analyses (by disease duration, concomitant csDMARD use, and baseline flare frequency) satisfied the journal’s demand for depth over breadth.
Why such reviews succeed at AC&R
- Patient‑centered focus – The review directly addresses a clinical decision that impacts daily quality of life, aligning with the journal’s mission to publish work that “measures what matters to patients.”
- dependable methodology – The network meta‑analysis provides actionable rankings, a rarity in rheumatology literature, and the authors pre‑registered their protocol on PROSPERO.
- International relevance – Data from Europe, North America, and Asia were pooled, reflecting the journal’s global author base and editorial board.
- Statistical rigor – The manuscript’s sensitivity analyses (leave‑one‑out, different prior distributions) were highlighted by reviewers as a model of transparency.
Mistake 5 (the hidden assumption): “If it’s not in a high‑IF journal, it won’t be cited”
While citation impact is a useful metric, citation patterns in rheumatology are highly skewed. Still, 8 × 5‑year impact factor** can still achieve >150 citations within five years if it addresses an unmet clinical need—exactly what the “RA treat‑to‑target” and “lupus nephritis social determinants” studies did. A paper published in AC&R with a **5.The journal’s open‑access option (no APC for ACR members) further broadens visibility, leading to higher download rates and, consequently, higher citation potential It's one of those things that adds up. Practical, not theoretical..
A quick reference guide for authors
| Decision point | AC&R advantage | Practical tip |
|---|---|---|
| Page charges | No charge for ACR members (vs. Consider this: $3 k APC in RMD Open) | Verify membership status early; request waiver for non‑members if funding is tight. |
| Statistical review | Mandatory pre‑specified analysis plans, multiple imputation, causal‑inference language | Prepare a statistical analysis plan (SAP) before data lock; include a missing‑data handling section. |
| Scope fit | Clinical epidemiology, outcomes research, patient‑centered trials, PROMIS work | Align the manuscript’s objectives with the journal’s patient‑centered outcomes theme. |
| Decision point | AC&R advantage | Practical tip |
|---|---|---|
| International collaboration | Welcomes multi‑regional consortia; editorial board includes representatives from North America, Europe, Asia‑Pacific, and Latin America. | Attach a brief PPI appendix summarizing how patient advisors shaped outcome selection (e. |
| Word limit | Generous allowance for methods‑heavy papers (up to 4,500 words for original research, 5,000 for systematic reviews). , forest plots with minimal clinically important difference thresholds, PROMIS score trajectories). Consider this: | |
| Open‑access options | No article‑processing charge for ACR members; discounted APC for non‑members via institutional agreements. | When drafting the author list, clearly delineate each site’s contribution (e. |
| Timeline | Median time from submission to first decision ≈ 4 weeks; average production time ≈ 6 weeks post‑acceptance. g. | |
| Figures & tables | Encourages informative, patient‑focused visuals (e.Day to day, g. | Plan your submission to coincide with major rheumatology conferences (e., a traffic‑light chart showing preferred biologic sequences for subgroups). Also, |
| Ethics & patient involvement | Requires explicit description of patient‑public‑involvement (PPI) activities and ethics approval numbers. g.Also, | Design at least one figure that translates statistical rankings into a clinical decision aid (e. , ACR/EULAR) to maximize timely dissemination and potential conference presentation opportunities. |
Conclusion
Choosing Arthritis Care & Research for your next manuscript means aligning with a journal that values patient‑centered relevance, methodological transparency, and global reach—without imposing prohibitive publication costs. Consider this: by leveraging the journal’s strengths—such as its open‑access waiver for ACR members, rigorous statistical review, and willingness to accommodate detailed methods sections—you can present a comprehensive, clinically actionable study that stands a strong chance of being read, cited, and ultimately influencing practice. So follow the practical tips outlined above, tailor your narrative to the journal’s emphasis on outcomes that matter to patients, and you will position your work for success in a venue that celebrates depth over breadth. Submit with confidence, knowing that AC&R’s editorial team is poised to support high‑quality rheumatology research that truly measures what matters.
